Record AUM and Midpoint Progress Toward Targets
Achieved record AUM before flow reinsurance of $73.1B (up 12% vs year-end 2024) and retained AUM of $57.6B (up 7% vs year-end 2024). AUM grew from a $51B 2020 baseline to $73B at year-end 2025 (a 44% increase toward the five-year 50% target).
Strong Sales Performance
Generated $14.6B of gross sales for FY2025 (second highest year on record), including $9.0B in core product sales and $5.6B in opportunistic sales. Q4 gross sales were $3.4B with core Q4 sales of $2.8B (up 27% sequentially from Q3).
Core Product Momentum
Indexed annuities $6.7B for FY2025 (in line with 2024) with Q4 indexed annuity sales of $1.9B (up 12% YoY). Indexed universal life (IUL) sales $190M for the year (up 14% YoY). Pension risk transfer (PRT) sales $2.1B for the year (third consecutive year ≥ $2B).
Improving Expense Efficiency
Operating expense ratio to AUM before flow reinsurance improved to 50 basis points at year-end 2025 from 60 basis points in 2024 (a 10 bps improvement). Company targets ~45 bps by year-end 2027.
High-Quality Investment Portfolio and Credit Metrics
Retained fixed maturities were 97% investment grade at year-end 2025. Private origination portfolio ~92% investment grade. Credit-related impairments remained stable at 8 basis points in 2025. Fixed income yield was 4.65% in Q4, up 6 bps YoY.
Growing Fee-Based Earnings
Fee income from flow reinsurance rose to $56M for FY2025 (up 37% vs $41M in 2024). Owned distribution margin contributed $47M (up 2% YoY). Fee-based strategies accounted for ~15% of adjusted net earnings in 2025 and management expects ~25% by year-end 2028.
Solid Adjusted Earnings and Capital Actions
Reported adjusted net earnings of $482M for FY2025 ($3.64 per share) and $123M in Q4 ($0.91). Company returned $137M of capital to shareholders in 2025, increased quarterly common dividend by 14% in Q4, and reported GAAP common equity excluding AOCI of $6.0B with book value per share excluding AOCI of $44.43 (up 62% since 2020 acquisition).
Strong Statutory Capital and Deleveraging Plan
Primary operating subsidiary company action level RBC approx. 430% (above 400% target). Targeting ~25% debt to capitalization excluding AOCI and expect balance sheet to naturally delever over time. Annualized interest expense ~$165M on $2.3B total debt.
Strategic Capital Transaction
On track to sell Bermuda legal entity F&G Life Re Limited to Ancient Financial Holdings LP (effective March 1). Recaptured ~$900M of affiliated statutory liabilities; expect net proceeds ≈ $300M (including a $200M dividend already reflected at year-end). Transaction provides capital transfer and counterparty diversification for MYGA flow reinsurance.